GlassScriptPhysician profile
Kaijun Huang
NPI 1043622814
$2,415.88
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,054 · 2020: $95.80 · 2021: $420 · 2022: $436 · 2023: $345 · 2024: $65.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $409.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $614.83 | 2019-2023 | Breztri, Farxiga |
| Lilly USA, LLC | $408.16 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Esperion Therapeutics, INC. | $168.72 | 2021 | |
| Amarin Pharma, INC. | $163.28 | 2019-2022 | |
| Gilead Sciences, INC. | $124.56 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $123.09 | 2019 | |
| Horizon Therapeutics Plc | $122.02 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $106.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.46 | 2019-2022 | |
| Glaxosmithkline, LLC. | $93.02 | 2019-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $87.52 | 2019 | |
| Novo Nordisk INC | $61.99 | 2023-2024 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $46.18 | 2019 | |
| Celgene Corporation | $45.70 | 2019 | |
| Amgen INC. | $43.52 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $40.53 | 2022 | |
| Pfizer INC. | $24.67 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $20.58 | 2019 | |
| Ibsa Pharma INC. | $15.73 | 2023 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaijun Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.